{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:19:39Z","timestamp":1790803179324,"version":"4.1.0"},"reference-count":161,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2014NextGenerationEU","award":["PE_00000019 \u201cHEAL ITALIA\u201d"],"award-info":[{"award-number":["PE_00000019 \u201cHEAL ITALIA\u201d"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Cystic fibrosis (CF) is a monogenic syndrome determined by over 2000 mutations in the CF Transmembrane Conductance Regulator (CFTR) gene harbored on chromosome 7. In people with CF (PWCF), lung disease is the major determinant of morbidity and mortality and is characterized by a clinical phenotype which differs in the presence of equal mutational assets, indicating that genetic and environmental modifiers play an important role in this variability. Airway inflammation determines the pathophysiology of CF lung disease (CFLD) both at its onset and progression. In this narrative review, we aim to depict the inflammatory process in CF lung, with a particular emphasis on those genetic polymorphisms that could modify the clinical outcome of the respiratory disease in PWCF. The natural history of CF has been changed since the introduction of CFTR modulator therapies in the clinical arena. However, also in this case, there is a patient-to-patient variable response. We provide an overview on inflammatory\/immunity gene variants that affect CFLD severity and an appraisal of the effects of CFTR modulator therapies on the inflammatory process in lung disease and how this knowledge may advance the optimization of the management of PWCF.<\/jats:p>","DOI":"10.3390\/genes14101966","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T07:22:32Z","timestamp":1697786552000},"page":"1966","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies"],"prefix":"10.3390","volume":"14","author":[{"given":"Annalucia","family":"Carbone","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Vitullo","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Support Center, Ospedale \u201cG. Tatarella\u201d, 71042 Cerignola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7246-5622","authenticated-orcid":false,"given":"Sante","family":"Di Gioia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3465-6641","authenticated-orcid":false,"given":"Massimo","family":"Conese","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Giacalone, V.D., Dobosh, B.S., Gaggar, A., Tirouvanziam, R., and Margaroli, C. (2020). Immunomodulation in Cystic Fibrosis: Why and How?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093331"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccm.2022.06.004","article-title":"Update on Innate and Adaptive Immunity in Cystic Fibrosis","volume":"43","author":"Bruscia","year":"2022","journal-title":"Clin. Chest Med."},{"key":"ref_7","unstructured":"The Cystic Fibrosis Centre at the Hospital for Sick Children (2011). Cystic Fibrosis Mutation Database, The Cystic Fibrosis Centre at the Hospital for Sick Children."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.med.58.071905.105316","article-title":"Airway surface dehydration in cystic fibrosis: Pathogenesis and therapy","volume":"58","author":"Boucher","year":"2007","journal-title":"Annu. Rev. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-0042-1758732","article-title":"Microbial Epidemiology of the Cystic Fibrosis Airways: Past, Present, and Future","volume":"44","author":"Thornton","year":"2023","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11130","article-title":"Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung","volume":"487","author":"Pezzulo","year":"2012","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI83922","article-title":"Acidic pH increases airway surface liquid viscosity in cystic fibrosis","volume":"126","author":"Tang","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18703","DOI":"10.1073\/pnas.1422091112","article-title":"pH modulates the activity and synergism of the airway surface liquid antimicrobials \u03b2-defensin-3 and LL-37","volume":"111","author":"Reznikov","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e97199","DOI":"10.1172\/jci.insight.97199","article-title":"Development of an airway mucus defect in the cystic fibrosis rat","volume":"3","author":"Birket","year":"2018","journal-title":"JCI Insight"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.98.11020330","article-title":"Influence of external pH on ciliary beat frequency in human bronchi and bronchioles","volume":"11","author":"Mouroux","year":"1998","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/thoraxjnl-2013-203204","article-title":"Airway inflammation in cystic fibrosis: Molecular mechanisms and clinical implications","volume":"68","author":"Kerem","year":"2013","journal-title":"Thorax"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1183\/09031936.00146807","article-title":"Inhibition of airway proteases in cystic fibrosis lung disease","volume":"32","author":"Griese","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.biocel.2008.03.003","article-title":"Proteases and cystic fibrosis","volume":"40","author":"Voynow","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1164\/rccm.201906-1190PP","article-title":"Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential","volume":"201","author":"McKelvey","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nm.2715","article-title":"Cystic fibrosis: A mucosal immunodeficiency syndrome","volume":"18","author":"Cohen","year":"2012","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/thx.2009.134106","article-title":"Airway remodelling and its relationship to inflammation in cystic fibrosis","volume":"66","author":"Regamey","year":"2011","journal-title":"Thorax"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1753425910370498","article-title":"Antibody equivalent molecules of the innate immune system: Parallels between innate and adaptive immune proteins","volume":"16","author":"Palaniyar","year":"2010","journal-title":"Innate Immun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1513\/pats.200508-090JS","article-title":"Innate immunity in the lungs","volume":"2","author":"Martin","year":"2005","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"587313","DOI":"10.3389\/fimmu.2021.587313","article-title":"Genetic Association with Pseudomonas aeruginosa Acquisition in Cystic Fibrosis: Influence of Surfactant Protein D and Mannose-Binding Lectin","volume":"12","author":"Freitag","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1165\/ajrcmb.23.3.3949","article-title":"Exaggerated activation of nuclear factor-kappaB and altered IkappaB-\u03b2 processing in cystic fibrosis bronchial epithelial cells","volume":"23","author":"Venkatakrishnan","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3389\/fimmu.2020.01438","article-title":"Role of Cystic Fibrosis Bronchial Epithelium in Neutrophil Chemotaxis","volume":"11","author":"Cabrini","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_27","first-page":"1309746","article-title":"Airway Epithelium Dysfunction in Cystic Fibrosis and COPD","volume":"2018","author":"Molloy","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1002\/ppul.23242","article-title":"Inflammation and its genesis in cystic fibrosis","volume":"50","author":"Nichols","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/JLB.5HI1117-454RR","article-title":"Frontline Science: Pathological conditioning of human neutrophils recruited to the airway milieu in cystic fibrosis","volume":"104","author":"Forrest","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1164\/rccm.201803-0442OC","article-title":"Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis","volume":"199","author":"Margaroli","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/JLB.4RU0620-245R","article-title":"Macrophage dysfunction in cystic fibrosis: Nature or nurture?","volume":"109","author":"Turton","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"L530","DOI":"10.1152\/ajplung.00621.2020","article-title":"CF monocyte-derived macrophages have an attenuated response to extracellular vesicles secreted by airway epithelial cells","volume":"320","author":"Koeppen","year":"2021","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1165\/rcmb.2008-0170OC","article-title":"Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator\u2212\/\u2212 mice","volume":"40","author":"Bruscia","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ncb1456","article-title":"CFTR regulates phagosome acidification in macrophages and alters bactericidal activity","volume":"8","author":"Di","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.abb.2016.06.015","article-title":"Abnormal activation of calpain and protein kinase Calpha promotes a constitutive release of matrix metalloproteinase 9 in peripheral blood mononuclear cells from cystic fibrosis patients","volume":"604","author":"Averna","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"31422","DOI":"10.1074\/jbc.M705296200","article-title":"Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages","volume":"282","author":"Haggie","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1091\/mbc.e09-01-0061","article-title":"Revisiting the role of cystic fibrosis transmembrane conductance regulator and counterion permeability in the pH regulation of endocytic organelles","volume":"20","author":"Barriere","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jcf.2019.09.003","article-title":"Human cystic fibrosis monocyte derived macrophages display no defect in acidification of phagolysosomes when measured by optical nanosensors","volume":"19","author":"Law","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1164\/rccm.201905-1013OC","article-title":"Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis","volume":"200","author":"McElvaney","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/rccm.202004-0991OC","article-title":"Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis","volume":"202","author":"Schupp","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000444687","article-title":"Toll-Like Receptors in Cystic Fibrosis: Impact of Dysfunctional microRNA on Innate Immune Responses in the Cystic Fibrosis Lung","volume":"8","author":"Vencken","year":"2016","journal-title":"J. Innate Immun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/thorax.58.7.613","article-title":"Expression of S100A12 (EN-RAGE) in cystic fibrosis","volume":"58","author":"Foell","year":"2003","journal-title":"Thorax"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2119\/molmed.2012.00024","article-title":"Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis","volume":"18","author":"Entezari","year":"2012","journal-title":"Mol. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1164\/rccm.200712-1894OC","article-title":"Potential role of high-mobility group box 1 in cystic fibrosis airway disease","volume":"178","author":"Rowe","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jcf.2015.12.011","article-title":"Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function","volume":"15","author":"Hunt","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1007\/s00018-020-03540-9","article-title":"Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations","volume":"77","author":"Holbrook","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e49248","DOI":"10.7554\/eLife.49248","article-title":"ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis","volume":"8","author":"Scambler","year":"2019","journal-title":"eLife"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1002\/ppul.24462","article-title":"Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL-1 signaling pathway","volume":"54","author":"Balazs","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.1038\/ncomms10791","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis","volume":"7","author":"Iannitti","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3389\/fimmu.2019.01789","article-title":"Metabolic Reprograming of Cystic Fibrosis Macrophages via the IRE1alpha Arm of the Unfolded Protein Response Results in Exacerbated Inflammation","volume":"10","author":"Scambler","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jcf.2018.05.006","article-title":"Interleukin-1 is associated with inflammation and structural lung disease in young children with cystic fibrosis","volume":"17","author":"Montgomery","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/adc.2004.069419","article-title":"New insights into pulmonary inflammation in cystic fibrosis","volume":"91","author":"Rao","year":"2006","journal-title":"Arch. Dis. Child."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1600903","DOI":"10.1183\/13993003.00903-2016","article-title":"Hypoxia and sterile inflammation in cystic fibrosis airways: Mechanisms and potential therapies","volume":"49","author":"Montgomery","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1165\/rcmb.2014-0250OC","article-title":"Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs","volume":"52","author":"Keiser","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1801771","DOI":"10.1183\/13993003.01771-2018","article-title":"The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis","volume":"54","author":"Rosenow","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12931-019-1103-1","article-title":"CFTR regulates B cell activation and lymphoid follicle development","volume":"20","author":"Polverino","year":"2019","journal-title":"Respir. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1164\/rccm.201407-1381OC","article-title":"Regulatory T-cell impairment in cystic fibrosis patients with chronic pseudomonas infection","volume":"191","author":"Hector","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.201102-0236OC","article-title":"The Th17 pathway in cystic fibrosis lung disease","volume":"184","author":"Tan","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.201104-0617ED","article-title":"IL-17 in cystic fibrosis: More than just Th17 cells","volume":"184","author":"Dubin","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1128\/IAI.00284-16","article-title":"Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation","volume":"84","author":"Hsu","year":"2016","journal-title":"Infect. Immun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1465-9921-11-177","article-title":"Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable Cystic Fibrosis patients","volume":"11","author":"Decraene","year":"2010","journal-title":"Respir. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/thoraxjnl-2013-203307","article-title":"IL-17 in lung disease: Friend or foe?","volume":"68","author":"Tan","year":"2013","journal-title":"Thorax"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic Fibrosis Modulator Therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Robinson","year":"2023","journal-title":"Lancet"},{"key":"ref_67","first-page":"CD009841","article-title":"Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis","volume":"1","author":"Skilton","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1164\/rccm.201704-0717OC","article-title":"Tezacaftor\/Ivacaftor in Subjects with Cystic Fibrosis and F508del\/F508del-CFTR or F508del\/G551D-CFTR","volume":"197","author":"Donaldson","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Munck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2019.00121","article-title":"Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine","volume":"10","author":"Pranke","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Sepahzad, A., Morris-Rosendahl, D.J., and Davies, J.C. (2021). Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine. Genes, 12.","DOI":"10.3390\/genes12040562"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa051469","article-title":"Genetic modifiers of lung disease in cystic fibrosis","volume":"353","author":"Drumm","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.chembiol.2014.02.021","article-title":"VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface","volume":"21","author":"Eckford","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"344ra384","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Bacalhau, M., Camargo, M., Magalhaes-Ghiotto, G.A.V., Drumond, S., Castelletti, C.H.M., and Lopes-Pacheco, M. (2023). Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030410"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mesinele, J., Ruffin, M., Guillot, L., and Corvol, H. (2022). Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214205"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcf.2005.05.006","article-title":"Disease modifying genes in cystic fibrosis","volume":"4","author":"Slieker","year":"2005","journal-title":"J. Cyst. Fibros."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biocel.2014.02.011","article-title":"Lung disease modifier genes in cystic fibrosis","volume":"52","author":"Guillot","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/j.1462-5822.2007.00953.x","article-title":"Pulmonary collectins in innate immunity of the lung","volume":"9","author":"Kuroki","year":"2007","journal-title":"Cell. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1172\/JCI6861","article-title":"Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis","volume":"104","author":"Garred","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1164\/rccm.200301-005OC","article-title":"Bronchoalveolar lavage fluid surfactant protein-A and surfactant protein-D are inversely related to inflammation in early cystic fibrosis","volume":"168","author":"Noah","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_87","first-page":"1040","article-title":"Complex two-gene modulation of lung disease severity in children with cystic fibrosis","volume":"118","author":"Dorfman","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_88","first-page":"165","article-title":"Use of diplotypes\u2014matched haplotype pairs from homologous chromosomes\u2014in gene-disease association studies","volume":"26","author":"Zuo","year":"2014","journal-title":"Shanghai Arch. Psychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3389\/fimmu.2018.02256","article-title":"Genetic Association of Pulmonary Surfactant Protein Genes, SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD With Cystic Fibrosis","volume":"9","author":"Lin","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.4049\/jimmunol.174.3.1638","article-title":"TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells","volume":"174","author":"Greene","year":"2005","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.humimm.2013.08.282","article-title":"Genetic variations in toll-like receptor pathway and lung function decline in Cystic fibrosis patients","volume":"74","author":"Haerynck","year":"2013","journal-title":"Hum. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7731","DOI":"10.4049\/jimmunol.1001513","article-title":"TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis","volume":"185","author":"Blohmke","year":"2010","journal-title":"J. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Beucher, J., Boelle, P.Y., Busson, P.F., Muselet-Charlier, C., Clement, A., Corvol, H., and The French C F Modifier Gene Study Investigators (2012). AGER\u2212429T\/C is associated with an increased lung disease severity in cystic fibrosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041913"},{"key":"ref_94","first-page":"43","article-title":"The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases","volume":"8","author":"Pelegrin","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s42269-023-01005-0","article-title":"NLRP3 inflammasome as a novel target for cystic fibrosis treatment","volume":"47","author":"Atalay","year":"2023","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1165\/rcmb.2020-0257OC","article-title":"Inflammasome Genetic Variants, Macrophage Function, and Clinical Outcomes in Cystic Fibrosis","volume":"65","author":"Graustein","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2174\/1389450117666151209120516","article-title":"Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target","volume":"17","author":"Guan","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/gene.2008.42","article-title":"Modulation of cystic fibrosis lung disease by variants in interleukin-8","volume":"9","author":"Hillian","year":"2008","journal-title":"Genes Immun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jcf.2014.04.007","article-title":"Cytokine gene polymorphisms and severity of CF lung disease","volume":"13","author":"Griffiths","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/jmg.2010.080937","article-title":"Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia","volume":"48","author":"Stanke","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/ejhg.2011.129","article-title":"Initial interrogation, confirmation and fine mapping of modifying genes: STAT3, IL1B and IFNGR1 determine cystic fibrosis disease manifestation","volume":"19","author":"Labenski","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","article-title":"The TNF and TNF receptor superfamilies: Integrating mammalian biology","volume":"104","author":"Locksley","year":"2001","journal-title":"Cell"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1479-5876-11-19","article-title":"TNF gene polymorphisms in cystic fibrosis patients: Contribution to the disease progression","volume":"11","author":"Shmarina","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00408-020-00320-x","article-title":"Association of Serum TGF-beta1 Levels with Different Clinical Phenotypes of Cystic Fibrosis Exacerbation","volume":"198","author":"Sagwal","year":"2020","journal-title":"Lung"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/ppul.20935","article-title":"Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis","volume":"43","author":"Corvol","year":"2008","journal-title":"Pediatr. Pulmonol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Trojan, T., Alejandre Alcazar, M.A., Fink, G., Thomassen, J.C., Maessenhausen, M.V., Rietschel, E., Schneider, P.M., and van Koningsbruggen-Rietschel, S. (2022). The effect of TGF-\u03b2(1) polymorphisms on pulmonary disease progression in patients with cystic fibrosis. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-022-01977-1"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00439-016-1684-4","article-title":"IL8 gene as modifier of cystic fibrosis: Unraveling the factors which influence clinical variability","volume":"135","author":"Furlan","year":"2016","journal-title":"Hum. Genet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"103584","DOI":"10.1016\/j.ejmg.2018.11.018","article-title":"TNFalpha \u2212857 C\/T and TNFR2 +587 T\/G polymorphisms are associated with cystic fibrosis in Iranian patients","volume":"62","author":"Hassanzad","year":"2019","journal-title":"Eur. J. Med. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Keown, K., Brown, R., Doherty, D.F., Houston, C., McKelvey, M.C., Creane, S., Linden, D., McAuley, D.F., Kidney, J.C., and Weldon, S. (2020). Airway Inflammation and Host Responses in the Era of CFTR Modulators. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176379"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Hadida","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ebiom.2014.12.005","article-title":"Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis","volume":"2","author":"Awatade","year":"2015","journal-title":"EBioMedicine"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3389\/fphar.2018.01429","article-title":"Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine","volume":"9","author":"Awatade","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Hadida","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e150398","DOI":"10.1172\/JCI150398","article-title":"Inflammatory cytokines TNF-\u03b1 and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators","volume":"131","author":"Rehman","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/rccm.202012-4332LE","article-title":"Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis","volume":"204","author":"McNally","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"642180","DOI":"10.3389\/fimmu.2021.642180","article-title":"Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid from Cystic Fibrosis Patients with a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid","volume":"12","author":"Mainz","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","article-title":"Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis","volume":"18","author":"Graeber","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Meoli, A., Eickmeier, O., Pisi, G., Fainardi, V., Zielen, S., and Esposito, S. (2022). Impact of CFTR Modulators on the Impaired Function of Phagocytes in Cystic Fibrosis Lung Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012421"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2014-02-555268","article-title":"A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy","volume":"124","author":"Pohl","year":"2014","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2015.02.010","article-title":"Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor","volume":"15","author":"Bratcher","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1165\/rcmb.2015-0322LE","article-title":"Ivacaftor-Induced Proteomic Changes Suggest Monocyte Defects May Contribute to the Pathogenesis of Cystic Fibrosis","volume":"54","author":"Hisert","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ppul.23712","article-title":"CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy","volume":"52","author":"Guerra","year":"2017","journal-title":"Pediatr. Pulmonol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2017.08.013","article-title":"Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease","volume":"23","author":"White","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"17066","DOI":"10.1038\/s41598-018-35151-7","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3389\/fphar.2020.01219","article-title":"CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People with Cystic Fibrosis","volume":"11","author":"Hisert","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Pedrazzi, M., Vercellone, S., Barberis, E., Capraro, M., De Tullio, R., Cresta, F., Casciaro, R., Castellani, C., Patrone, M., and Marengo, E. (2021). Identification of Potential Leukocyte Biomarkers Related to Drug Recovery of CFTR: Clinical Applications in Cystic Fibrosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083928"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2002161","DOI":"10.1183\/13993003.02161-2020","article-title":"Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations","volume":"57","author":"Hardisty","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"L432","DOI":"10.1152\/ajplung.00461.2017","article-title":"Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa","volume":"314","author":"Barnaby","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Currie, A.J., Main, E.T., Wilson, H.M., Armstrong-James, D., and Warris, A. (2020). CFTR Modulators Dampen Aspergillus-Induced Reactive Oxygen Species Production by Cystic Fibrosis Phagocytes. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.00372"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e54556","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Scambler","year":"2020","journal-title":"eLife"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"21700","DOI":"10.1038\/s41598-020-78817-x","article-title":"(R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages","volume":"10","author":"Shrestha","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Badr, A., Eltobgy, M., Krause, K., Hamilton, K., Estfanous, S., Daily, K.P., Abu Khweek, A., Hegazi, A., Anne, M.N.K., and Carafice, C. (2022). CFTR Modulators Restore Acidification of Autophago-Lysosomes and Bacterial Clearance in Cystic Fibrosis Macrophages. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.819554"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","article-title":"Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis","volume":"205","author":"Casey","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"L635","DOI":"10.1152\/ajplung.00198.2017","article-title":"Vx-809\/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells","volume":"314","author":"Ruffin","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1172\/JCI96273","article-title":"Clinically-approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia","volume":"129","author":"Borcherding","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Ribeiro, C.M.P., and Gentzsch, M. (2021). Impact of Airway Inflammation on the Efficacy of CFTR Modulators. Cells, 10.","DOI":"10.3390\/cells10113260"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"628722","DOI":"10.3389\/fphar.2021.628722","article-title":"Airway Epithelial Inflammation In Vitro Augments the Rescue of Mutant CFTR by Current CFTR Modulator Therapies","volume":"12","author":"Gentzsch","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Rehman, T., and Welsh, M.J. (2023). Inflammation as a Regulator of the Airway Surface Liquid pH in Cystic Fibrosis. Cells, 12.","DOI":"10.3390\/cells12081104"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.immuni.2017.11.010","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti Pseudomonas aeruginosa Immunity","volume":"47","author":"Riquelme","year":"2017","journal-title":"Immunity"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2102861","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","volume":"61","author":"Zhang","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"11995","DOI":"10.1038\/s41598-023-38300-9","article-title":"Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages","volume":"13","author":"Aridgides","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1180282","DOI":"10.3389\/fimmu.2023.1180282","article-title":"Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor-Tezacaftor-Ivacaftor treatment","volume":"14","author":"Schmidt","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2202096","DOI":"10.1183\/13993003.02096-2022","article-title":"Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis","volume":"61","author":"Dhote","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Bhagirath, A.Y., Li, Y., Somayajula, D., Dadashi, M., Badr, S., and Duan, K. (2016). Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm. Med., 16.","DOI":"10.1186\/s12890-016-0339-5"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Hampton, T.H., Thomas, D., van der Gast, C., O\u2019Toole, G.A., and Stanton, B.A. (2021). Mild Cystic Fibrosis Lung Disease Is Associated with Bacterial Community Stability. Microbiol. Spectr., 9.","DOI":"10.1128\/Spectrum.00029-21"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1164\/rccm.201701-0134OC","article-title":"Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity","volume":"197","author":"Polineni","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1038\/s41467-021-26777-9","article-title":"Epigenetic reprogramming of airway macrophages promotes polarization and inflammation in muco-obstructive lung disease","volume":"12","author":"Hey","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Butnariu, L.I., Tarca, E., Cojocaru, E., Rusu, C., Moisa, S.M., Leon Constantin, M.M., Gorduza, E.V., and Trandafir, L.M. (2021). Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245821"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cpt.2480","article-title":"Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design","volume":"111","author":"Dagenais","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Bomberger, J.M., Ye, S., Maceachran, D.P., Koeppen, K., Barnaby, R.L., O\u2019Toole, G.A., and Stanton, B.A. (2011). A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1001325"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"C357","DOI":"10.1152\/ajpcell.00373.2016","article-title":"Effects of Pseudomonas aeruginosa on CFTR chloride secretion and the host immune response","volume":"312","author":"Stanton","year":"2017","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ccm.2022.06.003","article-title":"Genetics of Cystic Fibrosis: Clinical Implications","volume":"43","author":"Joynt","year":"2022","journal-title":"Clin. Chest Med."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/10\/1966\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:09:03Z","timestamp":1760130543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/10\/1966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":161,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["genes14101966"],"URL":"https:\/\/doi.org\/10.3390\/genes14101966","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]}}}